Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Chordoma × nilotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8 Neoplasms 3 Leukemia, Myeloid, Chronic-Phase 2 Gastrointestinal Stromal Tumors 2 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm, Residual 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Non-Hodgkin 1 Leukemia 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Chordoma 1 Carcinoma, Squamous Cell 1 Blast Crisis 1 Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Imatinib Mesylate 2 spartalizumab 1 pembrolizumab 1 nilotinib 1 Thiotepa 1 Radiotherapy 1 Radiosurgery 1 Photochemotherapy 1 Peripheral Blood Stem Cell Transplantation 1 Pemetrexed 1 Panobinostat 1 Nivolumab 1 Melphalan 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Dihematoporphyrin Ether 1 Cyclophosphamide 1 Cetuximab 1 Busulfan 1 Bone Marrow Transplantation 1 Blood Specimen Collection 1 Bacterial Load 1 Amifostine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01407198 2025-12-19

Nilotinib With Radiation for High Risk Chordoma

Massachusetts General Hospital

Phase 1 Completed

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡